Objective To determine the change of maternal heart rate during the treatment with ritodrine for threatened premature labor. Methods110 cases of threatened premature labor were chosen. The ritodrine 100mg in 5% G. S 500mL was intravenously administered. The initial dosage was 6 drops/min, and the dose was increased until uterine contractions were inhibited. The treatment lasted for 40 to 48 hours after the uterine contractions were inhibited, then the oral tablets was recommended. If necessary, repeated treatment was given to some patients. The maternal heart rate was recorded in the whole process of treatment and was compared with the dosage administered. The labor time, fetal weight and Apgar′s score were also analyzed. Results The maternal basic heart rate was increased at first and then decreased. The increasing significantly increased( P ＜ 0.01 ) when the uterine contraction was inhibited. , but no difference showed among the groups of different gestational age( P＞0.05 ). The maternal heart rate was increased with the increasing of ritodrine( max. 140/min). labor time was significantly prolonged with the treatment of ritodrine( P＜0.01 ) ,while that of the idiopathic premature labor was prolonged most obviously ( P ＜ 0.05 ). Average fetal weight was (2.42 ± 0.49) kg, and the average Apgar′s score was≥8. Conclusion In the treatment of inhibiting uterine contractions,the increasing of maternal heart rate caused by ritodrine can be used as an indicator of therapeutic effect.

Objective To investigate the relationship between heat shock protein 70-2 (HSP70-2) gene polymorphism and diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM). Methods Following the inclusion and exclusion criteria, a total of 677 subjects were enrolled in present study. They were either hospitalized or undergoing regular health check-up in the Department of Nephrology of PLA 152nd Hospital in Pingdingshan of Henan Province. Among them 226 patients were suffering rom diabetes mellitus and nephrosis (DN group), 221 patients with 2DM but without nephrosis (DN group), and 230 were normal controls (NC group). Data were collected by questionnaire, physical examination and laboratory examination, and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was applied to detect the single nucleotide polymorphisms of HSP 70-2(+1267/G). Results The G/G genotype frequency of HSP70-2 was significantly higher in DN group than in DN and NC group (χ2 =8.123, P<0.01; χ2 =11.651, P<0.01); the G allele frequency of HSP70-2 was significantly higher in DN group than in DN and NC group (χ2 =9.392, P<0.01, OR=1.782; χ2 =11.971, P<0.01, OR=2.153). The levels of MALB/Cr and BMI were significantly higher in G/G gene carriers than in A/A gene carriers (P<0.05). Conclusion The G/G genotype of HSP70-2(+1267) maybe related to susceptibility to DN and general obesity; G allele carrier may have increased risk of T2DM with DN.

Atropine ; therapeutic use ; Humans ; Organophosphate Poisoning ; Poisoning ; drug therapy ; Quinuclidines ; therapeutic use

Humans ; Neoplasms ; epidemiology ; etiology ; Translational Medical Research

Molecular Epidemiology ; Neoplasms ; epidemiology ; etiology ; genetics

OBJECTIVE: To observe the effect and mechanisms of Bauhinia championii flavones(BCF) on hypoxia/reoxygenation (H/R) myocardial cells of neoanatal rats. METHODS: The cardiomyocytes hypoxia/reoxygenation injury model was developed, and Bauhinia championii flavones was pretreated (final concentration as 50, 100, 200 mg·L-1 respectively). The morphological changes of cardiomyocytes were observed by invert microscope. ELISA was used to evaluate the activities of tumor necrosis factor alpha, the protein expression of Bcl-2, Bax and NF-κβ was observed by immunohisto-chemistry, and Annex v-FITC/PI staining was used to detect apoptosis rate. RESULTS: Compared with model group, Bauhinia championii flavones pretreatment eased cardiomyocytes injury, decreased the activities of TNF-α and iNO S, maintained the eNOS level, up-regulated the expression of Bcl-2, down-regulated Bax and NF-κβ, and inhibited cadiocyte apoptosis (P<0.01 or P<0.05). CONCLUSION: BCF has protective effects on hypoxia/reoxygenation injury, which are associated with adjusting iNOS and NF-κβ signal channel, up-regulating Bcl-2, down-regulating Bax and NF-κβ, and inhibiting cadiocyte apoptosis.

Objective To study the application of super-selective external carotid artery embolization in head and neck diseases. Methods DSA and super-selective external carotid artery embolization were carried out in 41 cases of head and neck diseases including 12 cases of epistaxis,7 nasopharyngeal fibroangioma,1 traumatic arterial bleeding,14 vascular malformation,and 7 malignancies. Results No recurrence of nose bleeding after embolization of epistaxis was seen within 6 - 12-month follow up. The operative bleeding was reduced significantly by preoperative embolization in nasopharyngeal fibroangioma. No recurrence of bleeding was achieved after embolization of traumatic artery. Among the cases of vascular malformation,3 were proven to be significantly effcient,6 effcient,and 5 inefficent in the 6 - 12-month follow up. Among the 7 malignant cases,3 survived more than 2 years. Conclusion Super-selective external carotid artery embolization is safe and effective in the treatment of head and neck diseases. (J Intervent Radiol,2006,15: 330-332)

Animals ; Arrhythmias, Cardiac ; chemically induced ; prevention & control ; Cats ; Endothelin-1 ; adverse effects ; Medulla Oblongata ; drug effects ; Metoprolol ; pharmacology ; gamma-Aminobutyric Acid ; pharmacology

Obesity is becoming a chronic epidemic worldwide. Persistent obesity, in addition to triggering changes in skeletal muscle function and structure, may also lead to the occurrence of skeletal muscle atrophy, that maybe associate with autophagy and ubiquitin protea-some, interleukin-6, leptin, adiponectin, interleukin-10, tumor necrosis factor-alpha, growth hormone, angiotensin II, glucocorticoid, ad-vanced glycation end-product and myostatin, etc.

Objective:To explore the role of peripheral blood monocyte subsets in the pathogenesis of rheumatoid arthritis (RA),we therefore decided to compare the percentage of monocyte subpopulations in peripheral blood,as well as cytokines secretion function,to that of healthy controls. Methods:22 patients with RA and 22 cases of healthy controls ( HC) were drew 3 ml fresh venous blood into a tube containing heparin. The percentage of monocyte subsets,expression of Toll-like receptor(TLR)2,HLA-DR,triggering receptor expressed on myeloid cells-1(TREM-1) on intermediate monocyte and mean fluorescence intensity(MFI) of intracellular tumor necrosis factor-α ( TNF-α) were evaluated with the methods of flow cytometry ( FCM ) . The correlation between percentage of monocyte subsets and serum cytokines was explored. Statistical significance between parametric data was determined by the students't-test. Results:Compared to HC controls, the percentages of intermediate monocytes were significant higher in RA patients [ ( 11. 7 ± 1. 6)% vs (4. 6±1. 2)%,P<0. 05],as well as the expression(MFI) of TLR2 (750. 2±110. 3 vs 526. 8±98. 6) and TREM-1 (58. 4± 12. 1 vs 40. 3±10. 2) on intermediate monocytes (P<0. 05). The expression of HLA-DR on intermediate monocytes of RA patients had no difference with HC controls (P>0. 05),while MFI of intracellular TNF-αin intermediate monocytes of RA patients were significant higher than that of HC controls (46. 3±6. 4 vs 36. 7±8. 3,P<0. 05). In addition,RA patients showed a positive correlation between the percentage of CD14highCD16+ monocytes and DAS28 scores(r=0. 538,P=0. 009),as well as the serum levels of TNF-α,IL-17 ( r=0. 471,P=0. 027;r=0. 593,P=0. 003). Conclusion:Monocyte subpopulations from RA patients are abnormally skewed toward to in-termediate monocytes which has high expression of TLR2 , TREM-1 and the function of TNF-α secretion. Therefore, intermediate monocytes may play a role in the pathophysiology of RA. By modulating polarization or blocking monocyte cell surface receptors could be a new treatment of RA.